Clinical Overview
Haloperidol is a butyrophenone antipsychotic indicated for the treatment of schizophrenia, acute psychosis, delirium, severe behavioral problems in children, and Tourette’s disorder. It is one of the most potent typical antipsychotics and is available in oral, intramuscular, and long-acting injectable formulations for various clinical situations.
Primary Clinical Applications
Haloperidol is indicated for schizophrenia, acute psychotic episodes, delirium (especially in ICU settings), severe behavioral disorders in children with hyperactivity, and Tourette’s disorder. It is particularly valuable in emergency situations due to its rapid onset and high potency.
Mechanism and Clinical Considerations
As a potent dopamine D2 receptor antagonist, haloperidol effectively controls positive psychotic symptoms but carries high risk of extrapyramidal side effects. Its high potency allows for lower doses but requires careful monitoring for movement disorders and other adverse effects.
Formulation Advantages
Available as oral tablets, oral concentrate, intramuscular injection for acute situations, and long-acting decanoate injection for maintenance treatment. The decanoate formulation provides 4-week dosing intervals, improving adherence in chronic patients.
Prescribing Information
Dosing & Administration
Schizophrenia/Psychosis – Adults:
- Initial: 0.5-5 mg 2-3 times daily
- Maintenance: 1-15 mg daily
- Severe cases: Up to 100 mg daily
Acute Agitation (IM):
- Initial: 2-10 mg IM
- Repeat: Every 4-8 hours as needed
- Maximum: 20 mg daily
Tourette’s Disorder:
- Initial: 0.5-1.5 mg 2-3 times daily
- Range: 0.5-10 mg daily
Pediatric (3-12 years):
- Initial: 0.5 mg daily
- Range: 0.05-0.15 mg/kg/day
Decanoate (Long-acting):
- Initial: 10-15 times daily oral dose
- Maintenance: 50-200 mg every 4 weeks
Indications
- Schizophrenia
- Acute psychosis
- Delirium
- Tourette’s disorder
- Severe behavioral problems in children
Contraindications
- Severe CNS depression
- Comatose states
- Parkinson’s disease
- Known hypersensitivity to haloperidol
- Severe cardiac disease
Warnings & Precautions
- Boxed Warning: Increased mortality in elderly patients with dementia-related psychosis
- QT prolongation: Monitor ECG, especially with IV use
- Tardive dyskinesia: Risk increases with duration of treatment
- Neuroleptic malignant syndrome: Potentially fatal
- Extrapyramidal symptoms: High incidence, dose-related
- Sudden death: Reported with IV administration
Drug Interactions
- QT-prolonging drugs: Increased arrhythmia risk
- CNS depressants: Enhanced sedation
- Anticholinergics: May reduce haloperidol efficacy
- Lithium: Increased risk of extrapyramidal symptoms
- CYP3A4 inhibitors: Increased haloperidol levels
Adverse Reactions
Common:
- Extrapyramidal symptoms, sedation, restlessness
Serious:
- Tardive dyskinesia, neuroleptic malignant syndrome, QT prolongation
Metabolic:
- Hyperprolactinemia, weight gain, glucose abnormalities
Special Populations
- Elderly: Increased mortality risk in dementia patients
- Pregnancy: Category C – use only if benefits outweigh risks
- Hepatic impairment: Use with caution, monitor closely
- Pediatric: Higher risk of extrapyramidal symptoms
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
